In particular, cases with a high NPM1 mutational burden are associated with a higher probability of rapid transition to AML (at a median of 5 months) with myelomonocytic (M4) or monocytic (M5) differentiation and a poorer outcome, even when treated with chemotherapy (38, 39). The gene discussed is NPM1; the disease is acute myeloid leukemia.